The Effect of Ablation Therapy on Barrett's Esophagus

To assess the effect of ablative therapy (Photodynamic Therapy or Radiofrequency ablation ) on Barrett's Esophagus

Enrolling by Invitation

Interested in participating?

Key information

Conditions

Barrett's Esophagus Adenocarcinoma Of Esophagus Barrett Esophagus Digestive System Diseases Early Esophageal Adenocarcinoma Esophageal Diseases Gastrointestinal Diseases Neoplasms Precancerous Conditions

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Mayo Clinic

Rochester, Minnesota, 55905, United States

About this study

To assess the effect of ablation therapy on Barrett's esophagus. Proposal Ablation therapy is an FDA approved treatment to decrease cancer risk in Barrett's esophagus mucosa. This is being performed in our Barrett's Esophagus Unit on a regular basis. However, the longterm outcomes of this therapy is not established and there are patients who have been treated who later re-develop Barrett's mucosa. This study will allow us store tissue samples that can later be used to assess the effect of ablative therapy on Barrett's esophagus.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients who have had or qualify for ablation therapy for treatment of their barrett's esophagus with high grade dysplasia or early esophageal adenocarcinoma
Ability to provide informed consent

Exclusion criteria

Eastern Cooperative Oncology Group performance status 3 or 4
Inability to tolerate endoscopic procedures
Pregnancy: Females of child-bearing age will be screened with pregnancy test.

Treatment and study plan

Biopsy

Other

Biopsies for research purposes will be obtained when returning for clinically indicated surveillance of Barrett's Esophagus

Primary outcomes

Response to treatment

Time frame: at time of surveillance intervals

presence of persistent or recurrence of barrett's esophagus and/or dysplasia

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Acronym: ablation IN BE

Important dates

Study start: 2004
Primary completion: 2029
Study completion: 2029
First posted: Jan 7, 2008
Registry last updated: Mar 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed